相关实验视频
Updated: Sep 10, 2025

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
将药物代谢物转化为双β-上腺素受体-碳酸无水酶调节剂作为治疗眼部疾病的潜在工具
Andrea Ammara1, Alessandra Carone1, Laura Lucarini2
1NEUROFARBA Department, Sezione di Scienze Farmaceutiche e Nutraceutiche, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, Florence 50019, Italy.
研究人员化学修改了mirabegron的代谢物,制造了双重向的碳酸无水酶抑制剂和β3上腺素受体激活剂. 化合物14在体内显著降低眼内压力,这表明可能治疗眼睛高血压.
科学领域:
- 医学化学
- 药理学
- 眼科 眼科
背景情况:
- 米拉贝格伦是一种β3上腺素受体 (β3-AR) 激动剂,用于过度活跃的膀.
- 其主要代谢物 (R) - 2 - 3 - 4 - 氨基氨基) - 1 - 乙醇在很大程度上尚未被探索.
- 碳酸酶抑制剂 (CAI) 用于通过降低眼内压力 (IOP) 来治疗青光眼.
研究的目的:
- 合成和描述结合CAI和β3-AR激动因子的新型双目标化合物.
- 评估这些化合物的体外和体外疗效,特别是降低内血压.
- 探索这些衍生品在眼科应用和药物发现方面的潜力.
主要方法:
- 米拉贝格朗的主要代谢物的区域选择性化学衍生.
- 在体外对人类碳酸无水体 (hCA) 的抑制测定.
- 在体外评估β3-AR亚型激动性.
- 在瞬态眼高血压模型中的眼内压力 (IOP) 降低的体内评估.
- 在子血和隔离猪视网膜动脉中的血管扩张试验中进行了体外稳定性研究.
- 关键化合物的黑色素积累研究.
主要成果:
- 新型碳酸盐 (10-14) 和尿素 (15-18) 衍生物的合成.
- 这些化合物表现出明显的hCA抑制特征和偏好的β3-AR激动性.
- 化合物14在体内显著降低了内血压,在120分钟后效果最大.
- 化合物显示出高血稳定性,并诱导了视网膜动脉的血管扩张.
- 代表性化合物 (14, 16) 显示出明显的黑色体积累.
结论:
- 这种新型的双重向配体来自于mirabegron代谢物,可用于治疗眼部疾病.
- 这些化合物的机制可能涉及水性幽默的减少和眼血管调节.
- 这项研究突显了生物医学重新利用的潜力, 并为药物发现提供了新的策略.
更多相关视频
07:49Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
Published on: September 17, 2014
09:20Novel Photoacoustic Microscopy and Optical Coherence Tomography Dual-modality Chorioretinal Imaging in Living Rabbit Eyes
Published on: February 8, 2018
相关概念视频
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Adrenergic Agonists: Therapeutic Classification
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...